A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor — OSAT

Metastatic Renal Cell Carcinoma (mRCC) Clinical Trial

Official title:
Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment

Status Completed

Clinical Trial Summary

This is a Norwegian prospective registration, observational study of patients with advanced renal cell cancer on Afinitor treatment after failure of one Tyrosine Kinase Inhibitor (TKI) ( e.g. sunitinib or sorafenib). The goal is to document the treatment algorithm of these patients in Norway and the efficacy and tolerability of Afinitor® in a pure 2.line setting.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Carcinoma, Renal Cell
Metastatic Renal Cell Carcinoma (mRCC)

Clinical Trial Details

NCT number	NCT01390519
Study type	Observational
Source	Novartis
Contact
Status	Completed
Phase	N/A
Start date	June 2011
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04175262` - Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Completed	`NCT02184416` - Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
Completed	`NCT01514448` - Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib	Phase 4
Recruiting	`NCT05287464` - International Multicentric Study ARON-1